"Heqirui is committed to the research, development and commercialization of the first innovative drugs, targeting the widespread male and female diseases, with the goal of improving the quality of life. At present, Heqirui Pharmaceutical Co., Ltd. has announced the completion of Series A financing and has signed a global exclusive license agreement with Bayer AG for the development and industrialization of monoclonal antibodies targeting the prolactin (PRL) receptor. In accordance with the license agreement, Heqirui Medicine will develop and industrialize a new antibody targeting the prolactin (PRL) receptor globally based on Bayer's intellectual property rights. Potential indications for this antibody include male and female pattern alopecia, endometriosis, and other chronic diseases.
Prolactin (PRL) receptor antibody is a monoclonal antibody that targets the prolactin receptor, blocking the signaling pathway downstream of prolactin in a non-competitive manner. The mode of administration is subcutaneous injection. The antibody showed good tolerability in phase I clinical trials (including single-dose and multiple-dose administration). At the same time, studies have found that this antibody can effectively promote the hair growth of elderly red-faced monkeys. After 6 months of treatment, the number of terminal hairs in the alopecia area has nearly doubled, even in areas that were almost completely bald before, and the effect has continued to reach More than two years after stopping the drug. This research is the result of close cooperation between Bayer and Peking University Institute of Molecular Medicine scientists, and it is expected to be used in the treatment of male and female alopecia in the future."
· 和其瑞医药有限公司联合创始人、董事长兼首席执行官;· 北京大学讲席教授,北大分子医学研究所所长;· 《新英格兰医学期刊》副主编
www.njbpv.cn
I see hair loss mentioned first and in greater detail than the brief mention of endometriosis, which they never even bothered to try in macaques apparently.
This article has been revised unfortunately, but the initial print of it included quotes from Xiao Rui-Ping stating that Bayer was developing the drug for endometriosis, but they noticed it significantly increased the length of hair in mice. Xiao Rui-Ping was running the IMM in China, which has a NHP(non-human primate) facility. She was already working with Bayer on other things so she asked them if she could test the drug on her macaques for hair loss. When she saw the hair growth on the macaques she convinced Bayer to license the drug to her, and then created HMI. If it wasn't for the hair growth in macaques then HMI wouldn't even exist, so I don't know how you guys can think that it's not their primary indication. The only reason phase I was for endo is because it was Bayer's primary indication for the drug. If not for hair loss indication Bayer would have kept development in-house. They licensed it because they knew the hair loss indication would be profitable, but it didn't fit their pipeline. It is literally the only indication for which they KNOW the drug is effective. I expect Phase 2 trials to begin recruiting soon. You don't have to take my word for all this, many other people saw the original interview that was removed, and can backup what I'm saying. In every interview she talks about hair loss. The only mention of endometriosis is ever, "it can be used for endometriosis too".